{"id":52047,"date":"2022-12-15T18:03:12","date_gmt":"2022-12-15T17:03:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/"},"modified":"2022-12-15T18:03:12","modified_gmt":"2022-12-15T17:03:12","slug":"mpl-2021-premium-growth-not-sustained-in-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/","title":{"rendered":"MPL 2021 Premium Growth Not Sustained in 2022"},"content":{"rendered":"
\n

ROCKVILLE, Md.–(BUSINESS WIRE)–The medical liability insurance industry showed double-digit premium growth in 2021, driven by firmer pricing and a return to pre-pandemic levels of healthcare utilization, according to a new report released today from the Medical Professional Liability (MPL) Association. The report examines direct premiums written for physicians and hospitals, as well as other healthcare professionals and other facilities.\n<\/p>\n

<\/a><\/p>\n

\nMost companies recorded healthy premium increases in 2021 and the environment seemed primed for similar growth in 2022, the report, \u201cWhere Are MPL Premiums Heading<\/a>?\u201d found. However, MPL industry data as of June 30, 2022, shows that premium growth appears to have stalled.\n<\/p>\n

\n\u201cWhile the industry continues to show mid-single digit growth, most segments show much less growth than was recorded in 2021,\u201d said MPL Association Vice President of Research & Analytics Bill Burns. \u201cThe slowdown in growth was particularly sharp for the segments of \u2018other professionals\u2019 and \u2018other facilities\u2019 where premium increases were more than 25 percentage points less than in the same period in 2021.\u201d The MPL industry has not recorded an underwriting profit in almost a decade and continued pricing increases are likely needed to reverse this trend, Burns, noted.\n<\/p>\n

\nThe report is the first product from the Association\u2019s newly structured Research & Analytics Department, which will be issuing more MPL-specific industry analyses in 2023.\n<\/p>\n

\nThe report is available on the MPL Association website<\/a>.\n<\/p>\n

\nThe MPL Association is the leading international association representing medical professional liability insurance companies, risk retention groups, captives, trusts, and other entities with a commitment to the quality delivery of healthcare. MPL Association members insure nearly 2.5 million healthcare professionals around the world\u2014doctors, dentists, oral surgeons, nurses and nurse practitioners, podiatrists, and other healthcare providers. MPL Association members also insure more than 3,000 hospitals and 50,000 medical facilities and group practices globally.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBill Burns, Vice President, Research & Analytics, MPL Association
\n
908-210-6013, or bburns@MPLassociation.org<\/a><\/p>\n

Cassie Knapp, Vice President of Marketing & Communications, MPL Association
\n
301.947.9000, ext. 1218, or cknapp@MPLassociation.org<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ROCKVILLE, Md.–(BUSINESS WIRE)–The medical liability insurance industry showed double-digit premium growth in 2021, driven by firmer pricing and a return to pre-pandemic levels of healthcare utilization, according to a new report released today from the Medical Professional Liability (MPL) Association. The report examines direct premiums written for physicians and hospitals, as well as other healthcare … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52047","6":"format-standard","7":"category-industry"},"yoast_head":"\nMPL 2021 Premium Growth Not Sustained in 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MPL 2021 Premium Growth Not Sustained in 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md.–(BUSINESS WIRE)–The medical liability insurance industry showed double-digit premium growth in 2021, driven by firmer pricing and a return to pre-pandemic levels of healthcare utilization, according to a new report released today from the Medical Professional Liability (MPL) Association. The report examines direct premiums written for physicians and hospitals, as well as other healthcare ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-15T17:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221215005313\/en\/1665853\/21\/MPLA_Vertical_540C.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpl-2021-premium-growth-not-sustained-in-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpl-2021-premium-growth-not-sustained-in-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MPL 2021 Premium Growth Not Sustained in 2022\",\"datePublished\":\"2022-12-15T17:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpl-2021-premium-growth-not-sustained-in-2022\\\/\"},\"wordCount\":328,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpl-2021-premium-growth-not-sustained-in-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221215005313\\\/en\\\/1665853\\\/21\\\/MPLA_Vertical_540C.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpl-2021-premium-growth-not-sustained-in-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpl-2021-premium-growth-not-sustained-in-2022\\\/\",\"name\":\"MPL 2021 Premium Growth Not Sustained in 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpl-2021-premium-growth-not-sustained-in-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpl-2021-premium-growth-not-sustained-in-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221215005313\\\/en\\\/1665853\\\/21\\\/MPLA_Vertical_540C.jpg\",\"datePublished\":\"2022-12-15T17:03:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpl-2021-premium-growth-not-sustained-in-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpl-2021-premium-growth-not-sustained-in-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpl-2021-premium-growth-not-sustained-in-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221215005313\\\/en\\\/1665853\\\/21\\\/MPLA_Vertical_540C.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221215005313\\\/en\\\/1665853\\\/21\\\/MPLA_Vertical_540C.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mpl-2021-premium-growth-not-sustained-in-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MPL 2021 Premium Growth Not Sustained in 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MPL 2021 Premium Growth Not Sustained in 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/","og_locale":"en_US","og_type":"article","og_title":"MPL 2021 Premium Growth Not Sustained in 2022 - Pharma Trend","og_description":"ROCKVILLE, Md.–(BUSINESS WIRE)–The medical liability insurance industry showed double-digit premium growth in 2021, driven by firmer pricing and a return to pre-pandemic levels of healthcare utilization, according to a new report released today from the Medical Professional Liability (MPL) Association. The report examines direct premiums written for physicians and hospitals, as well as other healthcare ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-15T17:03:12+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221215005313\/en\/1665853\/21\/MPLA_Vertical_540C.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MPL 2021 Premium Growth Not Sustained in 2022","datePublished":"2022-12-15T17:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/"},"wordCount":328,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221215005313\/en\/1665853\/21\/MPLA_Vertical_540C.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/","url":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/","name":"MPL 2021 Premium Growth Not Sustained in 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221215005313\/en\/1665853\/21\/MPLA_Vertical_540C.jpg","datePublished":"2022-12-15T17:03:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221215005313\/en\/1665853\/21\/MPLA_Vertical_540C.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221215005313\/en\/1665853\/21\/MPLA_Vertical_540C.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/mpl-2021-premium-growth-not-sustained-in-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MPL 2021 Premium Growth Not Sustained in 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52047"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52047\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}